Loading...
•
Sep 30, 2021
Ironwood Pharmaceuticals Q3 2021 Earnings Report
Ironwood Pharmaceuticals' Q3 2021 performance was marked by prescription demand growth, U.S. net sales increase, profitability, and pipeline expansion.
Key Takeaways
Ironwood Pharmaceuticals reported Q3 2021 results, featuring a 12% year-over-year increase in LINZESS prescription demand, $253 million in LINZESS U.S. net sales (a 5% increase year-over-year), total revenue of $104 million, and GAAP net income of $56 million. The company ended the quarter with $574 million in cash and cash equivalents and expanded its pipeline through an option agreement with COUR Pharmaceuticals.
LINZESS prescription demand grew by 12% year-over-year.
LINZESS U.S. net sales reached $253 million, a 5% increase year-over-year.
Total revenue was reported at $104 million, with U.S. LINZESS collaboration revenue at $100 million.
GAAP net income was $56 million, and adjusted EBITDA was $65 million; the company ended Q3 2021 with $574 million in cash and cash equivalents.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals
Forward Guidance
Ironwood Pharmaceuticals reaffirmed its financial guidance for 2021, including expectations for U.S. LINZESS net sales growth, total revenue, and adjusted EBITDA.